SFN and Parkinson disease: Finally, because of their molecular interchangeability, ERN has shown in vitro and in vivo effects similar to those of SFN in SH-SY5Y cells simultaneously treated with 6-hydroxydopamine (6-OHDA) and in a 6-OHDA Parkinson’s disease (PD) mouse model, respectively [19].